Drug intelligence / Profile preview

EB-401

Development stage: Preclinical
Lead developer: Eluminex
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

EB-401 is a drug candidate being developed by Eluminex Biosciences. It is currently in the pre-IND (Investigational New Drug) stage of development and is intended for the treatment of Thyroid Eye Disease (TED). The drug is characterized as a bispecific antibody.

Beyond the preview

Go deeper on EB-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB-401.

Explore the full profile